{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:43:46Z","timestamp":1792727026961,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2010,10,14]],"date-time":"2010-10-14T00:00:00Z","timestamp":1287014400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1038\/nrc2946","type":"journal-article","created":{"date-parts":[[2010,10,14]],"date-time":"2010-10-14T10:04:45Z","timestamp":1287050685000},"page":"803-808","source":"Crossref","is-referenced-by-count":354,"title":["The genesis and evolution of high-grade serous ovarian cancer"],"prefix":"10.1038","volume":"10","author":[{"given":"David D. L.","family":"Bowtell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,10,14]]},"reference":[{"key":"BFnrc2946_CR1","volume-title":"World Cancer Report","author":"BW Stewart","year":"2003","unstructured":"Stewart, B. W. & Kleihues, P. World Cancer Report. (IARC Press, 2003)."},{"key":"BFnrc2946_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrc2644","volume":"9","author":"RC Bast Jr","year":"2009","unstructured":"Bast, R. C. Jr, Hennessy, B. & Mills, G. B. The biology of ovarian cancer: new opportunities for translation. Nature Rev. Cancer 9, 415\u2013428 (2009).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc2946_CR3","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1615\/CritRevOncog.v12.i3-4.50","volume":"12","author":"JR Jass","year":"2006","unstructured":"Jass, J. R. Colorectal cancer: a multipathway disease. Crit. Rev. Oncog. 12, 273\u2013287, (2006).","journal-title":"Crit. Rev. Oncog."},{"key":"BFnrc2946_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/00004347-200001000-00003","volume":"19","author":"SG Silverberg","year":"2000","unstructured":"Silverberg, S. G. Histopathologic grading of ovarian carcinoma: a review and proposal. Int. J. Gynecol. Pathol. 19, 7\u201315 (2000).","journal-title":"Int. J. Gynecol. Pathol."},{"key":"BFnrc2946_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/00000478-200303000-00001","volume":"27","author":"KR Lee","year":"2003","unstructured":"Lee, K. R. & Young, R. H. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am. J. Surg. Pathol. 27, 281\u2013292 (2003).","journal-title":"Am. J. Surg. Pathol."},{"key":"BFnrc2946_CR6","doi-asserted-by":"publisher","first-page":"6422","DOI":"10.1158\/1078-0432.CCR-05-0508","volume":"11","author":"KK Zorn","year":"2005","unstructured":"Zorn, K. K. et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin. Cancer Res. 11, 6422\u20136430 (2005).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc2946_CR7","first-page":"2913","volume":"63","author":"DR Schwartz","year":"2003","unstructured":"Schwartz, D. R. et al. Novel candidate targets of \u03b2-catenin\/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res. 63, 2913\u20132922 (2003).","journal-title":"Cancer Res."},{"key":"BFnrc2946_CR8","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","volume":"14","author":"RW Tothill","year":"2008","unstructured":"Tothill, R. W. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14, 5198\u20135208 (2008).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc2946_CR9","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1371\/journal.pmed.0050232","volume":"5","author":"M Kobel","year":"2008","unstructured":"Kobel, M. et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 5, e232 (2008).","journal-title":"PLoS Med."},{"key":"BFnrc2946_CR10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/PAP.0b013e3181b4fffa","volume":"16","author":"R Vang","year":"2009","unstructured":"Vang, R., Shih Ie, M. & Kurman, R. J. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv. Anat. Pathol. 16, 267\u2013282 (2009).","journal-title":"Adv. Anat. Pathol."},{"key":"BFnrc2946_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/path.2091","volume":"211","author":"Y Lee","year":"2007","unstructured":"Lee, Y. et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol. 211, 26\u201335 (2007).","journal-title":"J. Pathol."},{"key":"BFnrc2946_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.pap.0000201826.46978.e5","volume":"13","author":"Y Lee","year":"2006","unstructured":"Lee, Y. et al. Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv. Anat. Pathol. 13, 1\u20137 (2006).","journal-title":"Adv. Anat. Pathol."},{"key":"BFnrc2946_CR13","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ygyno.2008.01.012","volume":"109","author":"AK Folkins","year":"2008","unstructured":"Folkins, A. K. et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol. Oncol. 109, 168\u2013173 (2008).","journal-title":"Gynecol. Oncol."},{"key":"BFnrc2946_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3121\/cmr.2007.702","volume":"5","author":"CP Crum","year":"2007","unstructured":"Crum, C. P. et al. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin. Med. Res. 5, 35\u201344 (2007).","journal-title":"Clin. Med. Res."},{"key":"BFnrc2946_CR15","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1158\/1078-0432.CCR-07-4959","volume":"14","author":"AA Tone","year":"2008","unstructured":"Tone, A. A. et al. Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clin. Cancer Res. 14, 4067\u20134078 (2008).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc2946_CR16","doi-asserted-by":"publisher","first-page":"6116","DOI":"10.1158\/1078-0432.CCR-04-2509","volume":"11","author":"RT Marquez","year":"2005","unstructured":"Marquez, R. T. et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin. Cancer Res. 11, 6116\u20136126 (2005).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc2946_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","volume":"31","author":"DW Kindelberger","year":"2007","unstructured":"Kindelberger, D. W. et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol. 31, 161\u2013169 (2007).","journal-title":"Am. J. Surg. Pathol."},{"key":"BFnrc2946_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/path.2696","volume":"221","author":"AA Ahmed","year":"2010","unstructured":"Ahmed, A. A. et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 221, 49\u201356 (2010).","journal-title":"J. Pathol."},{"key":"BFnrc2946_CR19","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/jnci\/djj465","volume":"98","author":"HA Risch","year":"2006","unstructured":"Risch, H. A. et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J. Natl Cancer Inst. 98, 1694\u20131706 (2006).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrc2946_CR20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1146\/annurev.pathol.3.121806.151422","volume":"4","author":"AR Venkitaraman","year":"2009","unstructured":"Venkitaraman, A. R. Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu. Rev. Pathol. 4, 461\u2013487 (2009).","journal-title":"Annu. Rev. Pathol."},{"key":"BFnrc2946_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/jnci\/94.1.61","volume":"94","author":"JP Geisler","year":"2002","unstructured":"Geisler, J. P., Hatterman-Zogg, M. A., Rathe, J. A. & Buller, R. E. Frequency of BRCA1 dysfunction in ovarian cancer. J. Natl Cancer Inst. 94, 61\u201367 (2002).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrc2946_CR22","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1093\/jnci\/94.18.1396","volume":"94","author":"JL Hilton","year":"2002","unstructured":"Hilton, J. L. et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J. Natl Cancer Inst. 94, 1396\u20131406 (2002).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrc2946_CR23","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/sj.bjc.6604325","volume":"98","author":"SL Lim","year":"2008","unstructured":"Lim, S. L. et al. Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer. Br. J. Cancer 98, 1452\u20131456 (2008).","journal-title":"Br. J. Cancer"},{"key":"BFnrc2946_CR24","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4161\/cbt.5.3.2380","volume":"5","author":"Z Wang","year":"2006","unstructured":"Wang, Z., Li, M., Lu, S., Zhang, Y. & Wang, H. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway. Cancer Biol. Ther. 5, 256\u2013260 (2006).","journal-title":"Cancer Biol. Ther."},{"key":"BFnrc2946_CR25","first-page":"290","volume":"2","author":"AD D'Andrea","year":"2003","unstructured":"D'Andrea, A. D. The Fanconi Anemia\/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. Cell Cycle 2, 290\u2013292 (2003).","journal-title":"Cell Cycle"},{"key":"BFnrc2946_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2407-8-17","volume":"8","author":"JZ Press","year":"2008","unstructured":"Press, J. Z. et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8, 17 (2008).","journal-title":"BMC Cancer"},{"key":"BFnrc2946_CR27","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1093\/jnci\/94.13.990","volume":"94","author":"AA Jazaeri","year":"2002","unstructured":"Jazaeri, A. A. et al. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J. Natl Cancer Inst. 94, 990\u20131000 (2002).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrc2946_CR28","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1097-2765(00)80035-0","volume":"1","author":"KJ Patel","year":"1998","unstructured":"Patel, K. J. et al. Involvement of BRCA2 in DNA repair. Mol. Cell 1, 347\u2013357 (1998).","journal-title":"Mol. Cell"},{"key":"BFnrc2946_CR29","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S1097-2765(00)80466-9","volume":"3","author":"X Xu","year":"1999","unstructured":"Xu, X. et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol. Cell 3, 389\u2013395 (1999).","journal-title":"Mol. Cell"},{"key":"BFnrc2946_CR30","unstructured":"Norquist, B. M. et al. The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer 27 July 2010 (doi:10.1002\/cncr.25439)."},{"key":"BFnrc2946_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/path.2624","volume":"220","author":"W Xian","year":"2010","unstructured":"Xian, W. et al. The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube. J. Pathol. 220, 17\u201323 (2010).","journal-title":"J. Pathol."},{"key":"BFnrc2946_CR32","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/onc.2009.402","volume":"29","author":"K Levanon","year":"2010","unstructured":"Levanon, K. et al. Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene 29, 1103\u20131113 (2010).","journal-title":"Oncogene"},{"key":"BFnrc2946_CR33","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/sj.onc.1209170","volume":"25","author":"EA Williamson","year":"2006","unstructured":"Williamson, E. A. et al. BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27Kip1. Oncogene 25, 1391\u20131399 (2006).","journal-title":"Oncogene"},{"key":"BFnrc2946_CR34","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1038\/sj.onc.1205461","volume":"21","author":"EA Williamson","year":"2002","unstructured":"Williamson, E. A., Dadmanesh, F. & Koeffler, H. P. BRCA1 transactivates the cyclin-dependent kinase inhibitor p27Kip1. Oncogene 21, 3199\u20133206 (2002).","journal-title":"Oncogene"},{"key":"BFnrc2946_CR35","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0092-8674(03)00930-9","volume":"115","author":"L Hughes-Davies","year":"2003","unstructured":"Hughes-Davies, L. et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115, 523\u2013535 (2003).","journal-title":"Cell"},{"key":"BFnrc2946_CR36","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1158\/1078-0432.CCR-08-1564","volume":"15","author":"D Etemadmoghadam","year":"2009","unstructured":"Etemadmoghadam, D. et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin. Cancer Res. 15, 1417\u20131427 (2009).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc2946_CR37","unstructured":"Gorringe, K. L. et al. Genome-wide survey of copy number associations in ovarian cancer. PLoS ONE (in the press)."},{"key":"BFnrc2946_CR38","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.molonc.2008.12.005","volume":"3","author":"KL Gorringe","year":"2009","unstructured":"Gorringe, K. L. & Campbell, I. G. Large-scale genomic analysis of ovarian carcinomas. Mol. Oncol. 3, 157\u2013164 (2009).","journal-title":"Mol. Oncol."},{"key":"BFnrc2946_CR39","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1200\/JCO.2006.09.0795","volume":"25","author":"MJ Birrer","year":"2007","unstructured":"Birrer, M. J. et al. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J. Clin. Oncol. 25, 2281\u20132287 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc2946_CR40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1755-8794-2-21","volume":"2","author":"PM Haverty","year":"2009","unstructured":"Haverty, P. M., Hon, L. S., Kaminker, J. S., Chant, J. & Zhang, Z. High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors. BMC Med. Genomics 2, 21 (2009).","journal-title":"BMC Med. Genomics"},{"key":"BFnrc2946_CR41","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1158\/1078-0432.CCR-08-1878","volume":"15","author":"R Natrajan","year":"2009","unstructured":"Natrajan, R. et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin. Cancer Res. 15, 2711\u20132722 (2009).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc2946_CR42","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s12282-008-0034-3","volume":"15","author":"S Kobayashi","year":"2008","unstructured":"Kobayashi, S. Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance. Breast Cancer 15, 153\u2013158 (2008).","journal-title":"Breast Cancer"},{"key":"BFnrc2946_CR43","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1158\/0008-5472.CAN-08-1560","volume":"69","author":"E Manie","year":"2009","unstructured":"Manie, E. et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res. 69, 663\u2013671 (2009).","journal-title":"Cancer Res."},{"key":"BFnrc2946_CR44","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1158\/0008-5472.CAN-08-3426","volume":"69","author":"H Holstege","year":"2009","unstructured":"Holstege, H. et al. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res. 69, 3625\u20133633 (2009).","journal-title":"Cancer Res."},{"key":"BFnrc2946_CR45","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/nature08645","volume":"462","author":"PJ Stephens","year":"2009","unstructured":"Stephens, P. J. et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462, 1005\u20131010 (2009).","journal-title":"Nature"},{"key":"BFnrc2946_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/12640","volume":"23","author":"JR Pollack","year":"1999","unstructured":"Pollack, J. R. et al. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nature Genet. 23, 41\u201346 (1999).","journal-title":"Nature Genet."},{"key":"BFnrc2946_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1097-2765(00)80182-3","volume":"4","author":"H Lee","year":"1999","unstructured":"Lee, H. et al. Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, BRCA2. Mol. Cell 4, 1\u201310 (1999).","journal-title":"Mol. Cell"},{"key":"BFnrc2946_CR48","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/nrc2013","volume":"6","author":"LM Merlo","year":"2006","unstructured":"Merlo, L. M., Pepper, J. W., Reid, B. J. & Maley, C. C. Cancer as an evolutionary and ecological process. Nature Rev. Cancer 6, 924\u2013935 (2006).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc2946_CR49","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrc2819","volume":"10","author":"J van Riggelen","year":"2010","unstructured":"van Riggelen, J., Yetil, A. & Felsher, D. W. MYC as a regulator of ribosome biogenesis and protein synthesis. Nature Rev. Cancer 10, 301\u2013309 (2010).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc2946_CR50","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ccr.2005.06.010","volume":"8","author":"KR Loeb","year":"2005","unstructured":"Loeb, K. R. et al. A mouse model for cyclin E-dependent genetic instability and tumorigenesis. Cancer Cell 8, 35\u201347 (2005).","journal-title":"Cancer Cell"},{"key":"BFnrc2946_CR51","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/45836","volume":"401","author":"CH Spruck","year":"1999","unstructured":"Spruck, C. H., Won, K. A. & Reed, S. I. Deregulated cyclin E induces chromosome instability. Nature 401, 297\u2013300 (1999).","journal-title":"Nature"},{"key":"BFnrc2946_CR52","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.ajhg.2010.02.008","volume":"86","author":"JM Flanagan","year":"2010","unstructured":"Flanagan, J. M. et al. DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status. Am. J. Hum. Genet. 86, 420\u2013433 (2010).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrc2946_CR53","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/scientificamerican0307-50","volume":"296","author":"FS Collins","year":"2007","unstructured":"Collins, F. S. & Barker, A. D. Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. Sci. Am. 296, 50\u201357 (2007).","journal-title":"Sci. Am."},{"key":"BFnrc2946_CR54","doi-asserted-by":"crossref","unstructured":"The International Cancer Genome Consortium. International network of cancer genome projects. Nature 464, 993\u2013998 (2010).","DOI":"10.1038\/nature08987"},{"key":"BFnrc2946_CR55","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/emmm.200900041","volume":"1","author":"AM Mendes-Pereira","year":"2009","unstructured":"Mendes-Pereira, A. M. et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1, 315\u2013322 (2009).","journal-title":"EMBO Mol. Med."},{"key":"BFnrc2946_CR56","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/nature06548","volume":"451","author":"SL Edwards","year":"2008","unstructured":"Edwards, S. L. et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111\u20131115 (2008).","journal-title":"Nature"},{"key":"BFnrc2946_CR57","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1158\/0008-5472.CAN-08-0088","volume":"68","author":"EM Swisher","year":"2008","unstructured":"Swisher, E. M. et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68, 2581\u20132586 (2008).","journal-title":"Cancer Res."},{"key":"BFnrc2946_CR58","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/nature06633","volume":"451","author":"W Sakai","year":"2008","unstructured":"Sakai, W. et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116\u20131120 (2008).","journal-title":"Nature"},{"key":"BFnrc2946_CR59","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/nrc1457","volume":"4","author":"N Turner","year":"2004","unstructured":"Turner, N., Tutt, A. & Ashworth, A. Hallmarks of 'BRCAness' in sporadic cancers. Nature Rev. Cancer 4, 814\u2013819 (2004).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc2946_CR60","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","volume":"28","author":"PC Fong","year":"2010","unstructured":"Fong, P. C. et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 28, 2512\u20132519 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc2946_CR61","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123\u2013134 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrc2946_CR62","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1200\/jco.2010.28.15_suppl.3002","volume":"28","author":"KA Gelmon","year":"2010","unstructured":"Gelmon, K. A. et al. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. J. Clin. Oncol. Abstr. 28, 3002 (2010).","journal-title":"J. Clin. Oncol. Abstr."},{"key":"BFnrc2946_CR63","first-page":"1145","volume":"28","author":"DP Silver","year":"2010","unstructured":"Silver, D. P. et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J. Clin. Oncol. 28, 1145\u20131153 (2010).","journal-title":"cancer. J. Clin. Oncol."}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrc2946.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc2946","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc2946.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:30:27Z","timestamp":1684467027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrc2946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,14]]},"references-count":63,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["BFnrc2946"],"URL":"https:\/\/doi.org\/10.1038\/nrc2946","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,14]]}}}